Compound Detail
CHEMBL1201237
LEVOBUNOLOL 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL1201237 |
| Name | LEVOBUNOLOL |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | IXHBTMCLRNMKHZ-LBPRGKRZSA-N |
| Therapeutic | ✓ Yes |
6
Targets
12
Activities
2
Assay Types
0
PK Parameters
20
Publications
3
Known Names
1
Indications
Molecular Properties
291.4
MW (Da)
2.33
ALogP
4
HBA
2
HBD
58.6
PSA (Ų)
0.87
QED
0
Ro5 Violations
5
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1985 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Indications
Glaucoma
ATC Classification
S01ED03
levobunolol
Level 1: SENSORY ORGANS
Level 2: OPHTHALMOLOGICALS
Activity Summary
IC50 6 meas. best 9.1
Ki 6 meas. best 9.26
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Beta-2 adrenergic receptor CHEMBL210 | Ki | 9.26 | 9.26 | 0.5 | 1 |
| Beta-2 adrenergic receptor CHEMBL210 | IC50 | 9.1 | 9.1 | 0.8 | 1 |
| Beta-1 adrenergic receptor CHEMBL213 | Ki | 8.4 | 8.4 | 4.0 | 1 |
| Beta-1 adrenergic receptor CHEMBL213 | IC50 | 8.16 | 8.16 | 6.9 | 1 |
| Beta-3 adrenergic receptor CHEMBL246 | Ki | 6.59 | 6.59 | 255.0 | 1 |
| Sigma non-opioid intracellular receptor 1 CHEMBL287 | Ki | 6.49 | 6.49 | 325.0 | 1 |
| Beta-3 adrenergic receptor CHEMBL246 | IC50 | 6.47 | 6.47 | 340.0 | 1 |
| Sigma non-opioid intracellular receptor 1 CHEMBL287 | IC50 | 6.11 | 6.11 | 773.0 | 1 |
| 5-hydroxytryptamine receptor 1A CHEMBL273 | Ki | 5.78 | 5.78 | 1658.0 | 1 |
| Sodium-dependent serotonin transporter CHEMBL228 | Ki | 5.58 | 5.58 | 2602.0 | 1 |
| 5-hydroxytryptamine receptor 1A CHEMBL273 | IC50 | 5.54 | 5.54 | 2901.0 | 1 |
| Sodium-dependent serotonin transporter CHEMBL228 | IC50 | 5.31 | 5.31 | 4898.0 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 16472241 | 10.2174/1570163043334794 | Hepatotoxicity | 18 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| - | 10.1016/S0960-894X(97)00046-2 | ADMET | 4 |
| 37468498 | 10.1038/s41467-023-40064-9 | Thromboxane A2 receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Prostaglandin G/H synthase 1 | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M1 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Estrogen receptor | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Vascular endothelial growth factor receptor 2 | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 1A | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Mu-type opioid receptor | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-2A adrenergic receptor | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Sodium-dependent serotonin transporter | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Sodium-dependent noradrenaline transporter | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Acetylcholinesterase | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Voltage-gated inwardly rectifying potassium channel KCNH2 | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | D(1A) dopamine receptor | 1 |
| 38318365 | 10.1016/j.isci.2024.108907 | Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 | 1 |
Data from ChEMBL 36 via Core Engine